$GTCH on radar! GEN II Prototype qTerm Includes a Series of Enhancements
SAN DIEGO, May 26, 2021 (GLOBE NEWSWIRE) -- GBT Technologies Inc. (OTC PINK: GTCH) ("GBT”, or the “Company”) via GBT Tokenize Corp, completed generation II of its qTerm device. The GEN II release is a second version that includes a series of enhancements that target higher measurement accuracy, reliability and compatibility with a broader spectrum of users usage behavior. GBT's qTerm, a human vitals intelligent device is aimed to measure human vitals with a touch of a finger. Based on GEN I prototype testing, debugging and study, GBT’s concluded GEN II version to significantly advance the device’s general population compatibility. qTerm’s second release includes body temperature, blood oxygen and heart rate vitals with higher stability, and consistency to cover wider spectrum of users measurement habits. The device’s sensors were physically re-located to more efficient positions to enable best and consistent results. An additional coprocessor chip was installed to provide an advanced adjusting algorithm to support broader user’s measuring habits, compensating for different inputs and providing consistent results. Similar to the GEN I version, the GEN II device will be accompanied by a smartphone app and synchronized web application to keep a history and provide analytics for user's records at a later phase. The web application will be providing a geographical location and proximity alert to assist with potential health risks. GEN II series of modifications are done as part of the Company’s preparations for an FDA certification to classify qTerm as a medical device to be marketed and sold in the US. The certification process will be also aimed to define the device for telemedicine purposes enabling remote vitals results to be sent to clinics and hospitals for physicians review in real time. qTerm’s GEN II device is currently under testing for technical performance and commercial look-and-feel features evaluation.
"We are proud to announce the completion of our Gen II qTerm human vital device. We implemented a series of improvements in qTerm’s second release to achieve higher performance, accuracy, and user’s compatibility level. We put extra emphasis on the device ease of use, and user friendliness aspects. The device is currently under technical performance testing and commercial features look-and-feel evaluations. We strongly believe that qTerm can be an efficient, affordable health device in every household to assist with general health monitoring and early detection of symptoms and concerns. We are ever thriving to improve the device’s performance and capabilities, bringing it to the highest standards and regulations to enable people maintaining healthy life style," stated Danny Rittman, the Company’s Chief Technology Officer.
SAN DIEGO, May 26, 2021 (GLOBE NEWSWIRE) -- GBT Technologies Inc. (OTC PINK: GTCH) ("GBT”, or the “Company”) via GBT Tokenize Corp, completed generation II of its qTerm device. The GEN II release is a second version that includes a series of enhancements that target higher measurement accuracy, reliability and compatibility with a broader spectrum of users usage behavior. GBT's qTerm, a human vitals intelligent device is aimed to measure human vitals with a touch of a finger. Based on GEN I prototype testing, debugging and study, GBT’s concluded GEN II version to significantly advance the device’s general population compatibility. qTerm’s second release includes body temperature, blood oxygen and heart rate vitals with higher stability, and consistency to cover wider spectrum of users measurement habits. The device’s sensors were physically re-located to more efficient positions to enable best and consistent results. An additional coprocessor chip was installed to provide an advanced adjusting algorithm to support broader user’s measuring habits, compensating for different inputs and providing consistent results. Similar to the GEN I version, the GEN II device will be accompanied by a smartphone app and synchronized web application to keep a history and provide analytics for user's records at a later phase. The web application will be providing a geographical location and proximity alert to assist with potential health risks. GEN II series of modifications are done as part of the Company’s preparations for an FDA certification to classify qTerm as a medical device to be marketed and sold in the US. The certification process will be also aimed to define the device for telemedicine purposes enabling remote vitals results to be sent to clinics and hospitals for physicians review in real time. qTerm’s GEN II device is currently under testing for technical performance and commercial look-and-feel features evaluation.
"We are proud to announce the completion of our Gen II qTerm human vital device. We implemented a series of improvements in qTerm’s second release to achieve higher performance, accuracy, and user’s compatibility level. We put extra emphasis on the device ease of use, and user friendliness aspects. The device is currently under technical performance testing and commercial features look-and-feel evaluations. We strongly believe that qTerm can be an efficient, affordable health device in every household to assist with general health monitoring and early detection of symptoms and concerns. We are ever thriving to improve the device’s performance and capabilities, bringing it to the highest standards and regulations to enable people maintaining healthy life style," stated Danny Rittman, the Company’s Chief Technology Officer.
